Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
NeuroPace, Inc. develops and commercializes the RNS System, a brain-responsive neuromodulation device for treating drug-resistant focal epilepsy. The system monitors brain activity, recognizes abnormal patterns, and delivers targeted electrical pulses to prevent seizures. It provides clinicians with continuous data, supports personalized therapy, and improves patient outcomes. The company serves adult epilepsy patients, primarily in the U.S., with a focus on expanding indications and markets.
This description was generated via AI from an annual report. Updated about 1 year ago.